European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia
NCP Cross, T Ernst, S Branford, JM Cayuela… - Leukemia, 2023 - nature.com
From the laboratory perspective, effective management of patients with chronic myeloid
leukemia (CML) requires accurate diagnosis, assessment of prognostic markers, sequential …
leukemia (CML) requires accurate diagnosis, assessment of prognostic markers, sequential …
Digital PCR as a new method for minimal residual disease monitoring and treatment free remission management in chronic myeloid leukemia patients: is it reliable?
The effective and sensitive monitoring of Minimal Residual Disease or Measurable Residual
Disease (MRD) is a very important aspect in the management of patients affected by …
Disease (MRD) is a very important aspect in the management of patients affected by …
Committed change of real-time quantitative PCR to droplet digital PCR for monitoring BCR::ABL1 transcripts in tyrosine kinase inhibitor treated CML
A Kongruang, N Limsuwanachot, S Magmuang… - …, 2023 - Taylor & Francis
Objectives We performed a feasibility study of an FDA-approved commercial ddPCR assay
to measure BCR:: ABL1 in CML patients treated using TKI therapy. Methods Assay …
to measure BCR:: ABL1 in CML patients treated using TKI therapy. Methods Assay …
Recommendations from the AML molecular MRD expert advisory board
The standard-of-care treatment for patients with acute myeloid leukemia (AML) is being
challenged by new classes of targeted therapies, including FLT3, IDH and BCL2 inhibitors …
challenged by new classes of targeted therapies, including FLT3, IDH and BCL2 inhibitors …
Gene Expression Pattern of ESPL1, PTTG1 and PTTG1IP Can Potentially Predict Response to TKI First-Line Treatment of Patients with Newly Diagnosed CML
E Christiani, N Naumann, C Weiss, B Spiess, H Kleiner… - Cancers, 2023 - mdpi.com
Simple Summary There is still a lack of reliable molecular predictors to achieve major
molecular response (MMR, BCR:: ABL1≤ 0.1% IS) within the first year of treatment with …
molecular response (MMR, BCR:: ABL1≤ 0.1% IS) within the first year of treatment with …
Kinetics of BCR:: ABL1 transcript levels and molecular relapse after tyrosine kinase inhibitors discontinuation in chronic myeloid leukemia patients: preliminary results …
B Murbach, G Duarte, L Palma, E Miranda… - Frontiers in …, 2024 - frontiersin.org
Tyrosine kinase inhibitors (TKI) have revolutionized the treatment of patients with chronic
myeloid leukemia. Patients who achieve sustained deep molecular response are eligible for …
myeloid leukemia. Patients who achieve sustained deep molecular response are eligible for …
Patient Versus Physician Perspective in the Management of Chronic Myeloid Leukemia During Treatment with Tyrosine Kinase Inhibitors
H Chen, Y Wen, Y Zeng, L Lin, B Sun, H Zhu, H He… - Oncology and …, 2024 - Springer
Introduction Chronic myeloid leukemia (CML) is a chronic disease with treatment-free
remission (TFR) increasingly regarded as a feasible goal of treatment. However, various …
remission (TFR) increasingly regarded as a feasible goal of treatment. However, various …
Spotlight on the real-world treatment of CML pts in Germany: a retrospective survey in private oncology practices
GN Franke, G Loewe, M Reiser, H Linde, A Josting… - Annals of …, 2024 - Springer
Clinical trials in chronic myeloid leukemia (CML) are usually carried out in specialized
centers whereas primary care for patients (pts) with CML is mainly provided by local …
centers whereas primary care for patients (pts) with CML is mainly provided by local …
Laboratory-developed Droplet Digital PCR Assay for Quantification of the JAK2V617F Mutation
Y Liu, C Han, J Li, S Xu, Z Xiao, Z Guo… - Global Medical …, 2024 - thieme-connect.com
Precise quantification of the JAK2 V617F mutation using highly sensitive assays is crucial for
diagnosis, treatment process monitoring, and prognostic prediction in myeloproliferative …
diagnosis, treatment process monitoring, and prognostic prediction in myeloproliferative …
Genetic alterations in myeloproliferative and myelodysplastic/myeloproliferative neoplasms–a practical guide to WHO-HAEM5
C Kühn, K Hörst, HM Kvasnicka, A Hochhaus… - Medizinische …, 2024 - degruyter.com
Abstract Within the World Health Organization (WHO) classification of haematopoietic
neoplasms, particularly its fifth version from 2022 (WHO-HAEM5), myeloid neoplasms are …
neoplasms, particularly its fifth version from 2022 (WHO-HAEM5), myeloid neoplasms are …